KALA BIO, Inc. (KALA) shares surged 22.16% to $1.13 in after-hours trading Wednesday, and the catalyst was pretty straightforward: a major investor just took a big swing on the struggling biotech.

Follow the Money

Securities and Exchange Commission filings reveal that Oxford Finance LLC scooped up 1.62 million common shares, giving the Delaware-based lender a 16.5% ownership stake in the clinical-stage company. That's not a minor position—Oxford Finance now holds sole voting and dispositive power over all those shares with no shared authority, according to SEC documents.

The math behind that 16.5% ownership is based on 9.82 million total shares, which includes 8.20 million shares outstanding as of November 18 according to the company's Form 10-Q, plus the 1.62 million fresh shares issued to Oxford Finance.

New Captain at the Helm

The Oxford Finance stake comes on the heels of a leadership shakeup. Last week, the board tapped investor David Lazar as Chief Executive Officer and Principal Executive Officer. Lazar brings pharma experience to the table—he previously served as CEO of NovaBay Pharmaceuticals Inc. (NBY).

The Bigger Picture

Here's the thing: even with Wednesday's after-hours pop, KALA BIO remains deep in the red for 2024. The Massachusetts-based biopharmaceutical company's stock is down 88% year-to-date. The company sports a tiny market capitalization of just $7.59 million and trades in a 52-week range of $0.61 to $20.58—a spread that tells its own story about volatility.

Price Action: KALA BIO closed Wednesday's regular session at $0.92, down 15.91%, before the after-hours surge.